Relmada Therapeutics (RLMD) Cash from Financing Activities (2012 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Cash from Financing Activities data on file, last reported at $156.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $156.6 million in Q1 2026; TTM through Mar 2026 was $250.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $93.6 million, up 232034.78% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $156.6 million, up from $93.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for RLMD reached as high as $156.6 million in Q1 2026 and fell as low as -$172487.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $32.8 million across 4 years, with a median of $569092.0 in 2022.
• Across the five-year window, Cash from Financing Activities slumped 99.75% in 2022 and soared 54386.89% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $409883.0 in 2022, then tumbled by 142.08% to -$172487.0 in 2024, then surged by 54386.89% to $93.6 million in 2025, then jumped by 67.21% to $156.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $156.6 million in Q1 2026, $93.6 million in Q4 2025, and -$172487.0 in Q4 2024.